This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount MT
SANOFI : Jefferies reaffirms its Buy rating ZD
SANOFI : Receives a Buy rating from Berenberg ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge RE
Market Update-Europe ends the day in the green, relieved after the 1st round of elections in France RE
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June MT
Sanofi could invest up to EUR1.5 bn in its German insulin production site-source RE
Sanofi eyes German insulin investment of up to $1.6 bln, source says RE
Sector Update: Health Care Stocks Mixed Premarket Monday MT
Wall Street Kicks Off H2 as US Equity Futures Waver Pre-Bell MT
'HB': Sanofi plans to invest billions in Frankfurt DP
New semester, new state of mind Our Logo
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion' RE
Sanofi Eyes Up to $1.61 Billion Investment at German Production Site MT
Sanofi Mulls Up to EUR1.5 Billion Investment in Germany MT
Sanofi eyes investment of up to $1.6 billion in Germany, Handelsblatt says RE
CAC40: caution prevails ahead of crucial deadlines CF
CAC40: consolidates solo, OAT/Bund spread widens to 81Pb CF
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data MT
Top Premarket Gainers MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment DJ
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study MT
CAC40: below 7600 pts, held back by the automotive sector CF
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
90.44 EUR
Average target price
108.1 EUR
Spread / Average Target
+19.52%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Completes Provention Bio Acquisition